Literature DB >> 21917086

Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?

Etsuko Hashimoto1, Katsutoshi Tokushige.   

Abstract

The incidence of hepatocellular carcinoma in non-viral-related chronic liver disease has gradually increased in Japan. Obesity and diabetes mellitus type 2 have been established as a significant risk factor for hepatocellular carcinoma (HCC) by epidemiologic observations and experimental studies. The risks of these factors for HCC are likely conferred by two factors: the increased risk for development of non-alcoholic steatohepatitis (NASH) and the carcinogenic potential of themselves. Hepatocellular carcinoma in NASH is difficult to evaluate because histological diagnosis is required for diagnosis of NASH, which can lead selection bias. Furthermore, end-stage NASH is in effect "burned-out" NASH, for which the diagnosis of NASH cannot be made any more. At all events, previous studies on the etiology of Japanese HCC showed that non-alcoholic fatty liver disease accounts for 1-5% of all HCC (male predominant, median age 72 years). They have high prevalences of obesity and/or diabetes mellitus type 2 and 10-75% of the HCC arose from non-cirrhotic livers. HCC in NASH may be of multicentric origin, similar to HCC based on viral hepatitis. Regular screening for HCC is extremely important especially in cirrhotic NASH patients and recurrence should be warned. In western and Asian countries, the prevalence of non-alcoholic fatty liver disease in the general population is increasing dramatically. Therefore, there is an urgent need to elucidate pathogenesis and clinical features of HCC in NASH. In this review we summarize current concepts for HCC in NASH.
© 2011 The Japan Society of Hepatology.

Entities:  

Year:  2011        PMID: 21917086     DOI: 10.1111/j.1872-034X.2011.00872.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  49 in total

Review 1.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy.

Authors:  Hideaki Miura; Masayoshi Ijichi; Yoshitaka Ando; Korenobu Hayama; Kuniko IIhara; Haruki Yamada; Yasutsugu Bandai
Journal:  Clin J Gastroenterol       Date:  2013-09-12

3.  Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.

Authors:  Christopher Leung; Sern Wei Yeoh; Desmond Patrick; Shara Ket; Kaye Marion; Paul Gow; Peter W Angus
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

Review 4.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Nonalcoholic fatty liver disease and hepatocellular carcinoma.

Authors:  Stephanie Klein; Jean-François Dufour
Journal:  Hepat Oncol       Date:  2017-10-30

6.  Hepatocellular carcinoma (HCC) in non-cirrhotic liver: clinical, radiological and pathological findings.

Authors:  Michele Di Martino; Luca Saba; Sandro Bosco; Massimo Rossi; Kirchin A Miles; Rossella Di Miscio; Concetta Valentina Lombardo; Elisabetta Tamponi; Mario Piga; Carlo Catalano
Journal:  Eur Radiol       Date:  2014-04-26       Impact factor: 5.315

7.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

Review 8.  Significant biomarkers for the management of hepatocellular carcinoma.

Authors:  Yasuteru Kondo; Osamu Kimura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2015-04-09

9.  Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

Authors:  Shingo Tanaka; Koji Miyanishi; Masayoshi Kobune; Yutaka Kawano; Toshifumi Hoki; Tomohiro Kubo; Tsuyoshi Hayashi; Tsutomu Sato; Yasushi Sato; Rishu Takimoto; Junji Kato
Journal:  J Gastroenterol       Date:  2013-01-19       Impact factor: 7.527

Review 10.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.